Napp’s medicines in inflammatory diseases include our first biosimilar medicine. We believe that biosimilar medicines represent a significant opportunity for the NHS and patients, and we are working with healthcare professionals and commissioners to help realise their potential and make a positive difference to patients suffering the debilitating effects of inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis and psoriasis.
Remsima®▼ (infliximab) 100 mg powder for concentrate for solution for infusion.
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effectsSPC PIL